The Subtype Identity of Testicular Cancer Cells Determines Their Immunostimulatory Activity in a Coculture Model.
NTERA-2
T cell
TCam-2
cytokines
inflammation
monocyte
non-seminoma
seminoma
testicular germ cell cancer
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 May 2023
05 May 2023
Historique:
received:
21
03
2023
revised:
20
04
2023
accepted:
02
05
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
Testicular germ cell cancer (TGCC) is subdivided into several subtypes. While seminomatous germ cell tumors (SGCT) are characterized by an intensive infiltration of immune cells which constitute a pro-inflammatory tumor micromilieu (TME), immune cells in non-seminomatous germ cell tumors (NSGCT) are differently composed and less abundant. Previously, we have shown that the seminomatous cell line TCam-2 promotes T cell and monocyte activation in a coculture model, resulting in mutual interactions between both cell types. Here we set out to compare this feature of TCam-2 cells with the non-seminomatous cell line NTERA-2. Peripheral blood T cells or monocytes cocultured with NTERA-2 cells failed to secrete relevant amounts of pro-inflammatory cytokines, and significantly downregulated the expression of genes encoding activation markers and effector molecules. In contrast, immune cells cocultured with TCam-2 cells produced IL-2, IL-6 and TNFα, and strongly upregulated the expression of multiple pro-inflammatory genes. Furthermore, the expression of genes involved in proliferation, stemness and subtype specification remained unaltered in NTERA-2 cells during coculture with T cells or monocytes, indicating the absence of mutual interactions. Collectively, our findings uncover fundamental differences between SGCT and NSGCT in their capability to generate a pro-inflammatory TME, which possibly impacts the clinical features and prognosis of both TGCC subtypes.
Identifiants
pubmed: 37174085
pii: cancers15092619
doi: 10.3390/cancers15092619
pmc: PMC10177190
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : Scholarship
Organisme : Deutsche Forschungsgemeinschaft
ID : RE 1631/17-1
Références
Int J Cancer. 2020 Mar 15;146(6):1592-1605
pubmed: 31583686
Cell Tissue Res. 2008 Feb;331(2):529-38
pubmed: 18008088
Int J Androl. 2007 Aug;30(4):350-65
pubmed: 17705808
Oncoimmunology. 2017 Mar 20;6(4):e1305535
pubmed: 28507813
Cancers (Basel). 2022 Aug 19;14(16):
pubmed: 36011006
Curr Med Chem. 2018;25(36):4785-4806
pubmed: 28707587
Genes Chromosomes Cancer. 2008 Mar;47(3):185-96
pubmed: 18050305
Crit Rev Oncol Hematol. 2007 Dec;64(3):182-97
pubmed: 17644403
Br J Cancer. 2022 Apr;126(6):937-947
pubmed: 35022523
Eur Urol. 2015 Dec;68(6):1054-68
pubmed: 26297604
Am J Surg Pathol. 2006 Jul;30(7):858-65
pubmed: 16819328
Pigment Cell Melanoma Res. 2015 Sep;28(5):490-500
pubmed: 25818762
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
Immunol Invest. 1995 May;24(4):607-18
pubmed: 7622197
Nat Rev Cancer. 2005 Mar;5(3):210-22
pubmed: 15738984
Int J Mol Sci. 2021 Jun 29;22(13):
pubmed: 34209703
Cells. 2022 Mar 04;11(5):
pubmed: 35269507
Oncogene. 2003 Mar 27;22(12):1880-91
pubmed: 12660824
Andrology. 2017 Jul;5(4):763-770
pubmed: 28544640
Hum Reprod. 2016 Oct;31(10):2192-202
pubmed: 27609978
J Reprod Immunol. 2013 Dec;100(2):135-45
pubmed: 24290033
Oncology (Williston Park). 2002 Feb;16(2):217-26, 229; discussion 230-2
pubmed: 11866137
J Immunother Cancer. 2017 Mar 21;5:28
pubmed: 28331617
Mech Dev. 2005 Sep;122(9):1034-42
pubmed: 16023837
J Proteome Res. 2019 Apr 5;18(4):1819-1826
pubmed: 30835130
Urology. 2013 Feb;81(2):464.e1-9
pubmed: 23374840
Rev Sci Tech. 1998 Apr;17(1):84-94
pubmed: 9638802
Eur J Immunol. 2017 Jul;47(7):1232-1242
pubmed: 28555838
Oncotarget. 2016 Jul 26;7(30):47095-47110
pubmed: 27283990
Histopathology. 2021 Mar;78(4):593-606
pubmed: 32970854
J Hematol Oncol. 2021 Mar 19;14(1):45
pubmed: 33741032
Hum Cell. 2020 Oct;33(4):930-937
pubmed: 32507979
Dis Markers. 2019 Sep 3;2019:8298524
pubmed: 31565104
Cancer Biol Ther. 2010 Sep 15;10(6):529-36
pubmed: 20855948
BMC Clin Pathol. 2012 Oct 15;12:19
pubmed: 23066729
Eur J Cancer. 2020 Jun;132:127-135
pubmed: 32361383
PLoS One. 2014 Jan 03;9(1):e83585
pubmed: 24404135
Genes Chromosomes Cancer. 2012 Jul;51(7):717-26
pubmed: 22489004
Int J Cancer. 1999 Dec 10;83(6):815-22
pubmed: 10597201